Evidence map›Paper›PMID 32755584›Full record

ArticleCell reports2020

Sialyl-Lewis

Florent Colomb, Leila B Giron, Leticia Kuri-Cervantes, Opeyemi S Adeniji, Tongcui Ma, Harsh Dweep, Emilie Battivelli, Eric Verdin, Clovis S Palmer, Hiroaki Tateno and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cell reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Advances in HIV Research Using Mass Cytometry.Current HIV/AIDS reports · 2023
    Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 3 countries.

Florent ColombThe Wistar Institute, Philadelphia, PA 19104, USA; Penn Center for AIDS Research (Penn CFAR), University of Pennsylvania, Philadelphia, PA 19104, USA.
Leila B GironThe Wistar Institute, Philadelphia, PA 19104, USA; Penn Center for AIDS Research (Penn CFAR), University of Pennsylvania, Philadelphia, PA 19104, USA.
Leticia Kuri-CervantesDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Penn Center for AIDS Research (Penn CFAR), University of Pennsylvania, Philadelphia, PA 19104, USA.
Opeyemi S AdenijiThe Wistar Institute, Philadelphia, PA 19104, USA; Penn Center for AIDS Research (Penn CFAR), University of Pennsylvania, Philadelphia, PA 19104, USA.
Tongcui MaUniversity of California, San Francisco, San Francisco, CA 94158, USA; Gladstone Institutes, San Francisco, CA 94158, USA.
Harsh DweepThe Wistar Institute, Philadelphia, PA 19104, USA.
Emilie BattivelliThe Buck Institute for Research on Aging, Novato, CA 94945, USA.
Eric VerdinThe Buck Institute for Research on Aging, Novato, CA 94945, USA.
Clovis S PalmerThe Burnet Institute, Melbourne, VIC 3004, Australia; Department of Infectious Diseases, Monash University, Melbourne, VIC 3004, Australia.
Hiroaki TatenoNational Institute of Advanced Industrial Science and Technology (AIST), 1-1-1 Higashi, Tsukuba, Ibaraki 305-8566, Japan.
Andrew V KossenkovThe Wistar Institute, Philadelphia, PA 19104, USA.
Nadia R RoanUniversity of California, San Francisco, San Francisco, CA 94158, USA; Gladstone Institutes, San Francisco, CA 94158, USA.
Michael R BettsDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Penn Center for AIDS Research (Penn CFAR), University of Pennsylvania, Philadelphia, PA 19104, USA.
Mohamed Abdel-MohsenThe Wistar Institute, Philadelphia, PA 19104, USA; Penn Center for AIDS Research (Penn CFAR), University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: mmohsen@wistar.org.
The Wistar Institute · USBuck Institute for Research on Aging · USGladstone Institutes · USPenn Center for AIDS Research · USBurnet Institute · AUNational Institute of Advanced Industrial Science and Technology · JP

Funding

Virus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI DAVID S METZGER · 1999 to 2026
$78.6M
Project 3: Identifying plasma biomarkers predicting time to HIV rebound after treatment interruptionP01AI131374 · NIAID · J. DAVID GLADSTONE INSTITUTES · PI ROAN, NADIA R · 2017 to 2021
$8.5M
Role of Intestinal Barrier Integrity in Modulating the Host Glycome During COVID-19R01DK123733 · NIDDK · WISTAR INSTITUTE · PI ABDEL MOHSEN, MOHAMED, KESHAVARZIAN, ALI · 2020 to 2024
$4.5M
Phenotypic and mechanistic analysis of the in vivo HIV latent reservoir by single-cell technologiesR01AI147777 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROAN, NADIA R · 2019 to 2022
$3.8M
Host Glycomic Modulation of HIV-associated Neuro-inflammation During Viral SuppressionR01NS117458 · NINDS · WISTAR INSTITUTE · PI ABDEL MOHSEN, MOHAMED, NDHLOVU, LISHOMWA C · 2020 to 2023
$3.4M
Sialic Acid Modulation of HIV-associated Chronic InflammagingR01AG062383 · NIA · WISTAR INSTITUTE · PI ABDEL MOHSEN, MOHAMED · 2019 to 2023
$3.0M
Elucidating the mechanism of progesterone-induced permissivity in the upperfemale reproductive tractR01AI127219 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROAN, NADIA R · 2016 to 2020
$2.1M
Exploring Cell-free Glycomic Interactions in HIV-associated Neurological DisordersR21NS106970 · NINDS · WISTAR INSTITUTE · PI ABDEL MOHSEN, MOHAMED, NDHLOVU, LISHOMWA C · 2017 to 2018
$507k
Role of Host Glycosylation in the Galectin-9-Mediated Reversal of HIV LatencyR21AI129636 · NIAID · WISTAR INSTITUTE · PI ABDEL MOHSEN, MOHAMED · 2017 to 2018
$496k
Host Glycomic Determinants of HIV Persistence in vivoR21AI143385 · NIAID · WISTAR INSTITUTE · PI ABDEL MOHSEN, MOHAMED · 2019 to 2020
$491k
NIAID NIH HHS P01 AI131374NIAID NIH HHS P30 AI045008NIAID NIH HHS R01 AI127219NIAID NIH HHS R01 AI147777NIAID NIH HHS R21 AI129636NIAID NIH HHS R21 AI143385NIA NIH HHS R01 AG062383NIDDK NIH HHS R01 DK123733NINDS NIH HHS R01 NS117458NINDS NIH HHS R21 NS106970
6 · The paper itself

Abstract

A comprehensive understanding of the phenotype of persistent HIV-infected cells, transcriptionally active and/or transcriptionally inactive, is imperative for developing a cure. The relevance of cell-surface glycosylation to HIV persistence has never been explored. We characterize the relationship between cell-surface glycomic signatures and persistent HIV transcription in vivo. We find that the cell surface of CD4

Indexed as

Antiretroviral Therapy, Highly ActiveTranscription, GeneticCarbohydratesCD4-Positive T-LymphocytesCell LineCell MembraneFucoseGlycomicsGlycosylationHIVHIV InfectionsHumansImmunologic MemoryLigandsLymphocyte ActivationSialyl Lewis X AntigenCarbohydratesFucoseLigandsSialyl Lewis X Antigencutaneous lymphocyte antigenfucoseglycosylationHIV persistenceHIV transcriptionSialyl-Lewis(X)T cell trafficking

Identifiers

PMID32755584
PMCPMC7432956
OpenAlexW3047036885

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.